Kijimea IBS
Natural health product licensed in Canada
- Licence holder
- Kijimea Inc.
- NPN or DIN-HM
- 80072152
- Status
- Active licence
- Licence date
- 19 August 2016
- Revision date
- 2 March 2017
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Bifidobacterium bifidum Source : Bifidobacterium bifidum - Cellule entière | 500,000,000 ufc | Not calculated |
| Bifidobacterium bifidum Source : MIMBb75 | 500,000,000 ufc | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Amidon de maïs, Dioxyde de silicium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps support intestinal/gastrointestinal health. Alleviates Irritable Bowel Syndrome (IBS) symptoms. Effective remedy for Irritable Bowel Syndrome (IBS) symptoms. Clinically shown to significantly reduce symptoms of Irritable Bowel Syndrome (IBS). First improvement of Irritable Bowel Syndrome (IBS) symptoms such as abdominal distension and bloating after 1 week. Significant improvement of Irritable Bowel Syndrome (IBS) symptoms such as abdominal pain and discomfort, abdominal distension and bloating and urgency of bowel movement after 2 weeks. Improves Irritable Bowel Syndrome (IBS) symptoms such as digestive disorder, abdominal pain and discomfort, abdominal distension, bloating and urgency of bowel movements. Clinically shown to significantly alleviate symptoms of Irritable Bowel Syndrome (IBS) and simultaneously improve the patient quality of life. Source of probiotics to significantly reduce symptoms of Irritable Bowel Syndrome (IBS).Aids in the management of Irritable Bowel Syndrome (IBS) symptoms such as digestive disorder, abdominal pain and discomfort, abdominal distension, bloating and urgency for bowel movements.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80072152
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2017. Photograph the packaging to check whether it has changed. Photograph the packaging